Table 1 New agents for immunotherapy of relapsed/refractory acute lymphoblastic leukemia
| Â | Blin | IO | 19-28Z CAR | 19-41BB CAR |
|---|---|---|---|---|
Phase | III | III | I | II |
Patients | ||||
 Age (year) | ≥ 18 | ≥ 18 | ≥ 18 | ≤ 21 |
 No. enrolled | 271 | 141 | 83 | 92 |
 No. evaluable | 267 | 109 | 53 | 75 |
Follow-up (m) | 11.7 | NA | 29 | 13.1 |
CR % | 44 | 80.7 | 83 | 81 |
EFS (m) | 7.3 | 5 (PFS) | 6.1 | NR |
OS (m) | 7.7 | 7.7 | 12.9 | NR |
CRS (≥ grade III %) | 4.9 | NA | 26 | 47 |
Neurotoxicity % | 9.4 | NA | 44 | 40 |
References | 11 | 12 | 31 | 32 |